NB S101: Completed Phase II enrollment

Osteologix completed enrollment of 289 postmenopausal women in the double-blind, U.K. and Danish Phase II STRONG trial comparing 750, 1,000 and 2,000 mg of once-daily NB S101 tablets vs. placebo for 1...